PD-1 Blockade and Allogeneic Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma, a Matter of Time: a National Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire

Overview

Journal Haematologica

Specialty Hematology

Date 2024 Jun 13

PMID 38867585

Authors

Eleonore Kaphan

Francois Bettega

Nicolas Vallet

Nathalie Fegueux

Marie Robin

Ali Bazarbachi

Stephanie Nguyen

David Beauvais

Edouard Forcade

Maria Carolina Montes De Oca

Raynier Devillier

Patrice Chevallier

Michael Loschi

Anne Huynh

Jacques-Olivier Bay

Marie-Therese Rubio

Felipe Suarez

Sylvie Francois

Xavier Poire

Nathalie Contentin

Deborah Desmier

Amandine Charbonnier

Jerome Cornillon

Sylvain Chantepie

Pascal Turlure

Claude-Eric Bulabois

David Michonneau

Alban Villate

Sfgm-Tc

Affiliations

Soon will be listed here.

References

Dada R, Usman B . Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety. Eur J Haematol. 2018; 102(2):150-156. DOI: 10.1111/ejh.13186. View

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P . Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14):1428-1439. PMC: 6075855. DOI: 10.1200/JCO.2017.76.0793. View

Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella A . Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010; 115(18):3671-7. DOI: 10.1182/blood-2009-12-253856. View

Longoria T, Tewari K . Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016; 12(10):1247-53. PMC: 5613934. DOI: 10.1080/17425255.2016.1216976. View

Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F . Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018; 132(1):9-16. DOI: 10.1182/blood-2018-02-811174. View

Holtan S, DeFor T, Lazaryan A, Bejanyan N, Arora M, Brunstein C . Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015; 125(8):1333-8. PMC: 4335084. DOI: 10.1182/blood-2014-10-609032. View

Ijaz A, Khan A, Malik S, Faridi W, Fraz M, Usman M . Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2018; 25(1):94-99. PMC: 6310648. DOI: 10.1016/j.bbmt.2018.08.028. View

Michonneau D, Sagoo P, Breart B, Garcia Z, Celli S, Bousso P . The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. Immunity. 2016; 44(1):143-154. DOI: 10.1016/j.immuni.2015.12.008. View

Merryman R, Castagna L, Giordano L, Ho V, Corradini P, Guidetti A . Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021; 35(9):2672-2683. DOI: 10.1038/s41375-021-01193-6. View

10.

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

11.

Martinez C, Carpio C, Heras I, Rios-Herranz E, Buch J, Gutierrez A . Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. Biol Blood Marrow Transplant. 2020; 26(8):1534-1542. DOI: 10.1016/j.bbmt.2020.02.003. View

12.

Jagasia M, Greinix H, Arora M, Williams K, Wolff D, Cowen E . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2014; 21(3):389-401.e1. PMC: 4329079. DOI: 10.1016/j.bbmt.2014.12.001. View